AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28957940 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic fibrinolysis (tenecteplase, TNK)
Number of subjects: 100
Study 28957940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24293225 — intervention group
Group type: EXPERIMENTAL
Intervention: R&R2MHP cognitive skills program (group treatment)
Number of subjects: 38
Study 24293225 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 38
Study 24092567 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 μg) + Formoterol (6 μg) on demand
Number of subjects: 66
Study 24092567 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular Budesonide (400 μg) on demand
Number of subjects: 66
Study 24092567 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (0.5 mg) on demand
Number of subjects: 66
Study 22532824 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination period (first 7 months of follow-up)
Number of subjects: 352
Study 22532824 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-vaccination period (after the vaccination period)
Number of subjects: 352
Study 22532824 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled at sites providing contraception on-site
Number of subjects: 352
Study 22532824 — intervention group
Group type: EXPERIMENTAL
Intervention: Entered the trial as injectable contraceptive users
Number of subjects: 352
Study 22532824 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom users
Number of subjects: 352
Study 22532824 — intervention group
Group type: EXPERIMENTAL
Intervention: Single partner whose status was HIV-negative
Number of subjects: 352
Study 22532824 — intervention group
Group type: EXPERIMENTAL
Intervention: Two partners both of HIV-unknown status
Number of subjects: 352
Study 22532824 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more risk factors (marijuana use, heavy drinking, or use of either during sex)
Number of subjects: 352
Study 19930556 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral decompressive craniectomy (DC)
Number of subjects: 74
Study 17538167 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 431
Study 15389234 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization of vessels > or =50% stenoses
Number of subjects: 219
Study 15389234 — intervention group
Group type: COMPARATOR
Intervention: Culprit vessel revascularization
Number of subjects: 219
Study 11788109 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal natural progesterone gel (4% or 8%) applied every other day for six doses per month
Number of subjects: 49
Study 9516567 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 88
Study 9516567 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CSA)
Number of subjects: 88
Study 8035269 — intervention group
Group type: EXPERIMENTAL
Intervention: Early repair (within 6 hours)
Number of subjects: 32
Study 8035269 — intervention group
Group type: COMPARATOR
Intervention: Delayed repair (at 96+ hours)
Number of subjects: 32
Study 3276451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ranitidine
Number of subjects: 26
Study 31150517 — intervention group
Group type: COMPARATOR
Intervention: 1-back task
Number of subjects: 28
Study 31150517 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-back task
Number of subjects: 28
Study 28696573 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Q waves on the presenting ECG
Number of subjects: 2723
Study 28696573 — intervention group
Group type: COMPARATOR
Intervention: Absence of Q waves on the presenting ECG
Number of subjects: 2723
Study 26188275 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 180
Study 26188275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary habits intervention
Number of subjects: 180
Study 24113391 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 60
Study 24113391 — intervention group
Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound (CDU)
Number of subjects: 60
Study 24113391 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography angiography (CTA)
Number of subjects: 60
Study 24113391 — intervention group
Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound (CDU) and Contrast-enhanced ultrasound (CEUS)
Number of subjects: 60
Study 20951752 — intervention group
Group type: EXPERIMENTAL
Intervention: DIET with miracle fruit
Number of subjects: 13
Study 20951752 — intervention group
Group type: COMPARATOR
Intervention: REG
Number of subjects: 13
Study 19181970 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg infusion)
Number of subjects: 50
Study 19181970 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 50
Study 19181970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (zoledronic acid and control)
Number of subjects: 50
Study 17539921 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 17539921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15486961 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 25
Study 15486961 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 25
Study 15486961 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 11600554 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (mean dose, 85.5 +/‐ 4.3 microg/d)
Number of subjects: 66
Study 11600554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 10175988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged prophylaxis with enoxaparin (low-molecular-weight heparin) administered during hospitalization and for 3 weeks after discharge
Number of subjects: 100000
Study 10175988 — intervention group
Group type: COMPARATOR
Intervention: Short term prophylaxis administered only during hospitalization
Number of subjects: 100000
Study 10175988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged LMWH prophylaxis with enoxaparin
Number of subjects: 100000
Study 8047703 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked with 18 trials of retroactive inhibition (BL-18)
Number of subjects: 0
Study 8047703 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked with 36 trials of retroactive inhibition (BL-36)
Number of subjects: 0
Study 8047703 — intervention group
Group type: COMPARATOR
Intervention: Blocked without retroactive inhibition (BL-without)
Number of subjects: 0
Study 8047703 — intervention group
Group type: COMPARATOR
Intervention: Random subjects
Number of subjects: 0
Study 3180390 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate‐adaptive temperature‐controlled pacing with Nova MR
Number of subjects: 7
Study 3180390 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate‐adaptive activity‐controlled pacing with Activitrax
Number of subjects: 7
Study 3180390 — intervention group
Group type: COMPARATOR
Intervention: VVI or AAI pacing at 70 beats/min (SSI 70)
Number of subjects: 7
Study 31752604 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy-based Training to Enhance Memory (STEM) - 8-session treatment protocol incorporating self-generation, spaced learning, and retrieval practice.
Number of subjects: 20
Study 31752604 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group (not specified in detail).
Number of subjects: 20
Study 29668397 — intervention group
Group type: EXPERIMENTAL
Intervention: LED treatment at 2.4 J/cm2 (wavelengths 625, 660, 850 nm) three times a week for 8 weeks
Number of subjects: 60
Study 29668397 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with light that simulated LED
Number of subjects: 60
Study 29668397 — intervention group
Group type: EXPERIMENTAL
Intervention: LED treatment
Number of subjects: 60
Study 29668397 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 28347337 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (structured moderate-intensity physical activity program)
Number of subjects: 1635
Study 28347337 — intervention group
Group type: COMPARATOR
Intervention: Health education program (control group)
Number of subjects: 1635
Study 28347337 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1635
Study 25081363 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml foam (22 kcal) consumed immediately after main meals (M)
Number of subjects: 134
Study 25081363 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml foam (22 kcal) consumed after snacks (S)
Number of subjects: 134
Study 25081363 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml foam (22 kcal) consumed in-between snacks and main meals (I)
Number of subjects: 134
Study 25081363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no foam)
Number of subjects: 134
Study 25081363 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam consumption at all timings (M, S, I)
Number of subjects: 134
Study 24034853 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke Free Homes educational programme
Number of subjects: 700
Study 24034853 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 700
Study 21399471 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation for stable intertrochanteric fractures (Group A)
Number of subjects: 100
Study 21399471 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation for unstable intertrochanteric fractures (Group B)
Number of subjects: 100
Study 18200431 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD with ADHD
Number of subjects: 40
Study 18200431 — intervention group
Group type: COMPARATOR
Intervention: OCD without ADHD
Number of subjects: 40
Study 16443598 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopathy
Number of subjects: 84
Study 16443598 — intervention group
Group type: COMPARATOR
Intervention: Control (heterosexual male confederate)
Number of subjects: 84
Study 15120552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-modal (auditory-visual) priming with regular verbs (with and without orthographically salient morphemic aspectual markers)
Number of subjects: 0
Study 15120552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-modal (auditory-visual) priming with irregular verbs
Number of subjects: 0
Study 11181383 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day quinine-clindamycin regimen (group QC)
Number of subjects: 108
Study 11181383 — intervention group
Group type: COMPARATOR
Intervention: 7-day quinine regimen (group Q)
Number of subjects: 108
Study 9074306 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (mean dose 440 mg +/- 123 mg)
Number of subjects: 150
Study 9074306 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (mean dose 35 mg +/- 8 mg)
Number of subjects: 150
Study 9074306 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (Control)
Number of subjects: 150
Study 9074306 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (Intervention)
Number of subjects: 150
Study 9074306 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 150
Study 8379625 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine on-table cholangiography (R)
Number of subjects: 167
Study 8379625 — intervention group
Group type: COMPARATOR
Intervention: Selective on-table cholangiography (S)
Number of subjects: 167
Study 3021407 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate, guar gum fiber (HCF) bars (35.7 g carbohydrate and 6.6 g guar gum/bar)
Number of subjects: 16
Study 3021407 — intervention group
Group type: COMPARATOR
Intervention: Placebo bars (identical except for the absence of guar gum)
Number of subjects: 16
Study 29119799 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith-based anti-stigma intervention
Number of subjects: 199
Study 29119799 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199
Study 27496046 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwegian Psychomotor Physiotherapy (NPMP)
Number of subjects: 0
Study 27496046 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Patient Education in combination with active individualized physiotherapy (COPE-PT)
Number of subjects: 0
Study 23716067 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus hydroxychloroquine plus sulfasalazine plus low-dose prednisone (arm 1)
Number of subjects: 610
Study 23716067 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus adalimumab (ADA) (arm 2)
Number of subjects: 610
Study 23716067 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with MTX and prednisone
Number of subjects: 610
Study 23716067 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 610
Study 22706949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 105% ICS (IE(105))
Number of subjects: 7
Study 22706949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 110% ICS (IE(110))
Number of subjects: 7
Study 22706949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 125% ICS decreased to 105% ICS (IE(125‐105))
Number of subjects: 7
Study 22706949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 125% ICS decreased to 110% ICS (IE(125‐110))
Number of subjects: 7
Study 19926503 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injection into the superior joint space (SJS)
Number of subjects: 30
Study 19926503 — intervention group
Group type: COMPARATOR
Intervention: Autologous blood injections to the SJS and the pericapsular tissues (PT)
Number of subjects: 30
Study 19926503 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 30
Study 18539084 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 20
Study 18539084 — intervention group
Group type: COMPARATOR
Intervention: Control group (constant medication)
Number of subjects: 20
Study 15316710 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 46
Study 15316710 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 46
Study 15316710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 12712782 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil infusion
Number of subjects: 25
Study 12712782 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anaesthesia
Number of subjects: 25
Study 10993127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-100 mg/day)
Number of subjects: 53
Study 10993127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8959316 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular NSAID use (at least twice weekly for 12 months or longer)
Number of subjects: 477
Study 8959316 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaspirin NSAID use
Number of subjects: 477
Study 8959316 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 477
Study 8959316 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-NSAID users)
Number of subjects: 477
Study 1388048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole 1 mg orally per day
Number of subjects: 80
Study 1388048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole 4 mg orally per day
Number of subjects: 80
Study 1388048 — intervention group
Group type: COMPARATOR
Intervention: Fadrozole (1 or 4 mg)
Number of subjects: 80
Study 3933029 — intervention group
Group type: EXPERIMENTAL
Intervention: + oxaprotiline
Number of subjects: 6
Study 3933029 — intervention group
Group type: EXPERIMENTAL
Intervention: desipramine
Number of subjects: 6
Study 3933029 — intervention group
Group type: EXPERIMENTAL
Intervention: - oxaprotiline
Number of subjects: 6
Study 3933029 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 29028463 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford ADHD protocol
Number of subjects: 35
Study 29028463 — intervention group
Group type: COMPARATOR
Intervention: Pre-protocol assessment
Number of subjects: 35
Study 27322481 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-422 high dose (>10(6)‐<10(7)CFU)
Number of subjects: 24
Study 27322481 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-422 low dose (>10(5)‐<10(6)CFU)
Number of subjects: 24
Study 27322481 — intervention group
Group type: COMPARATOR
Intervention: Tice BCG (1‐8×10(5)CFU)
Number of subjects: 24
Study 24296957 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ‐alexidine
Number of subjects: 0
Study 24296957 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ‐MAPDA
Number of subjects: 0
Study 24296957 — intervention group
Group type: EXPERIMENTAL
Intervention: balafilcon A
Number of subjects: 0
Study 22834768 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks treatment with vaginal progesterone
Number of subjects: 0
Study 22834768 — intervention group
Group type: COMPARATOR
Intervention: 8 weeks placebo
Number of subjects: 0
Study 20727543 — intervention group
Group type: EXPERIMENTAL
Intervention: Back fill technique
Number of subjects: 79
Study 20727543 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto fill technique
Number of subjects: 79
Study 20727543 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient outcomes
Number of subjects: 79
Study 18728521 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15238430 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-triggered tones (subjects pressed a button every 5 s)
Number of subjects: 12
Study 15238430 — intervention group
Group type: COMPARATOR
Intervention: Externally triggered tones (passively listened)
Number of subjects: 12
Study 12118018 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent thoracic radiotherapy (TRT)
Number of subjects: 231
Study 12118018 — intervention group
Group type: COMPARATOR
Intervention: Sequential thoracic radiotherapy (TRT)
Number of subjects: 231
Study 9703402 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal traction
Number of subjects: 78
Study 9703402 — intervention group
Group type: COMPARATOR
Intervention: Skin traction
Number of subjects: 78
Study 7851354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal infusion with a bolus dose of 100 micrograms morphine followed by a 24 h infusion of 200 micrograms morphine (8.3 micrograms h‐1)
Number of subjects: 55
Study 7851354 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion with a bolus dose of 2 mg of morphine followed by a 24 h infusion of morphine 200 micrograms h‐1 + 0.25% bupivacaine 4 ml h‐1
Number of subjects: 55
Study 2895963 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 760 (histamine H2-receptor antagonist)
Number of subjects: 12
Study 2895963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29045949 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Video Game Group (AVGG)
Number of subjects: 39
Study 29045949 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 39
Study 26798023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol Extended Release (ER)
Number of subjects: 2276
Study 25418493 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 22
Study 25418493 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 20 mg/d
Number of subjects: 22
Study 24184815 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) 16 mmol IV followed by 5 mmol over two hours
Number of subjects: 15
Study 24184815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21645424 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐administered, semiquantitative food frequency questionnaire (FFQ)
Number of subjects: 107
Study 21645424 — intervention group
Group type: COMPARATOR
Intervention: Three days of nonconsecutive three‐day food records (3D‐FRs)
Number of subjects: 107
Study 19114887 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% albumin (Alb: n = 59)
Number of subjects: 119
Study 19114887 — intervention group
Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch 130/0.4 (HES: n = 60)
Number of subjects: 119
Study 16774480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) - 24-hour intravenous infusion
Number of subjects: 49
Study 16774480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 15322436 — intervention group
Group type: EXPERIMENTAL
Intervention: CEI of 0.5% bupivacaine plus IEB of 0.5% bupivacaine 4 times daily (n = 29)
Number of subjects: 56
Study 15322436 — intervention group
Group type: COMPARATOR
Intervention: IEB of normal saline plus IEB of 0.5% bupivacaine 4 times daily (n = 27)
Number of subjects: 56
Study 11771598 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion (TCI) of propofol (3 to 8 microg/ml)
Number of subjects: 40
Study 11771598 — intervention group
Group type: COMPARATOR
Intervention: Manually Controlled Infusion (MCI) of propofol (approximately 2 mg/kg bolus and 3 to 10 mg/kg/h infusion)
Number of subjects: 40
Study 11771598 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion (TCI) of propofol
Number of subjects: 40
Study 11771598 — intervention group
Group type: COMPARATOR
Intervention: Manually Controlled Infusion (MCI) of propofol
Number of subjects: 40
Study 9402499 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis-containing mouthrinse
Number of subjects: 0
Study 9402499 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 0
Study 9402499 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 0
Study 9402499 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 0
Study 8499957 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral conjugated equine estrogens, 0.625 mg daily, with sequential oral dl‐norgestrel, 0.15 mg daily, for 12 days per month
Number of subjects: 96
Study 8499957 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal estradiol‐17 beta, 0.05 mg daily, with sequential transdermal norethindrone acetate, 0.25 mg daily, for 14 days per month
Number of subjects: 96
Study 8499957 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 96